The Endocrine Society has intensified its multi-front campaign to safeguard the future of biomedical research in the United States, targeting a controversial proposed rule by the Office of Management and Budget (OMB) that threatens to fundamentally alter the landscape of scientific funding. The proposed regulation, which has sparked widespread alarm across the scientific community, seeks to centralize control over federal grant awards, potentially shifting the decision-making power from non-partisan scientific experts to political appointees within the executive branch. As the October 1 implementation deadline approaches, the Endocrine Society is calling for the immediate withdrawal of the rule, warning that its adoption would dismantle the merit-based peer-review system that has served as the backbone of American innovation for decades.
For nearly a century, the United States has maintained its position as a global leader in biomedical discovery through a rigorous process of independent peer review, where grants are awarded based on scientific merit, feasibility, and the potential for public health impact. The OMB’s proposed rule, however, introduces several mechanisms that critics argue would allow for unprecedented political interference in the scientific process. By granting political appointees the authority to block awards that do not align with the specific policy priorities of a current administration, the rule could effectively censor research into sensitive or politically charged topics, ranging from reproductive health and climate change to endocrine-disrupting chemicals and gender-affirming care.
Core Provisions of the Proposed OMB Regulation
The proposed rule contains several specific provisions that the Endocrine Society and its allies have identified as direct threats to the stability and integrity of the U.S. research enterprise. Foremost among these is the expansion of "administrative discretion" in the awarding of federal grants. Under the new guidelines, federal agencies would be empowered to bypass the traditional peer-review recommendations if a project is deemed inconsistent with the executive branch’s "strategic objectives." This shift would transition the funding model from one of objective excellence to one of political compliance.
Furthermore, the rule would grant federal agencies the authority to terminate active research grants at any time without a formal appeals process. This lack of due process creates a precarious environment for researchers, particularly those involved in long-term longitudinal studies or multi-year clinical trials. The sudden withdrawal of funding could result in the loss of years of data, the dismissal of specialized laboratory staff, and the abandonment of critical public health inquiries.
The proposal also aims to impose significant restrictions on publication costs and international collaborations. Specifically, the rule seeks to limit the amount of federal funding that can be used for "open access" publishing fees, which could hinder the dissemination of taxpayer-funded research to the general public and the global scientific community. Additionally, new hurdles for international partnerships could stifle progress on global health issues, such as pandemic preparedness and the management of chronic diseases that require large-scale, cross-border data sharing.
A Chronology of Advocacy and Opposition
The Endocrine Society’s opposition to the OMB proposal has unfolded over several months of strategic advocacy, beginning shortly after the rule’s initial release in the early summer of 2024. Recognizing the existential threat the rule posed to endocrine science and broader biomedical research, the Society mobilized its leadership and membership to engage directly with federal lawmakers.
Throughout June and July, the Society submitted formal comments to the OMB, detailing the technical and ethical flaws in the proposal. These comments emphasized that endocrine research—which addresses conditions such as diabetes, obesity, thyroid disorders, and hormone-related cancers—often requires long-term investment and a stable funding environment that is insulated from political shifts.
In August, the advocacy efforts shifted to a high-intensity legislative campaign. A group of 50 Endocrine Society members, representing a diverse array of academic institutions and clinical practices, participated in a series of "rolling Zoom calls" with congressional staff. These virtual meetings allowed researchers to explain the real-world implications of the OMB rule to staffers who handle health and science portfolios. Following these calls, the Society brought several high-profile members to Washington, D.C., for in-person meetings with congressional leadership and key members of the House and Senate Appropriations Committees.
These efforts culminated in a significant legislative victory in September. Senator Susan Collins (R-ME), who serves as the Chair of the Senate Appropriations Committee, acknowledged the concerns raised by the scientific community. In response, she successfully included language in the Senate version of the short-term funding resolution—commonly known as a Continuing Resolution (CR)—to delay the implementation of the OMB rule. This delay provides a critical window for further debate and potential legislative action to permanently block the rule’s most damaging provisions.
Supporting Data: The Economic and Scientific Stakes
The potential disruption caused by the OMB rule is not merely a matter of administrative policy; it carries significant economic and public health risks. According to data from the National Institutes of Health (NIH), the agency invested approximately $47.5 billion in medical research in the 2023 fiscal year. This funding supports more than 300,000 researchers at more than 2,500 universities, medical schools, and other research institutions in every state and around the world.
Studies by the United for Medical Research (UMR) coalition indicate that every $1.00 of NIH funding generates approximately $2.46 in local economic activity. In 2023 alone, NIH-funded research supported 412,041 jobs and generated $92.89 billion in economic output across the United States. By introducing uncertainty into the grant-funding process and allowing for the arbitrary termination of awards, the OMB rule threatens this economic engine.
In the field of endocrinology specifically, the stakes are exceptionally high. Diabetes affects more than 38 million Americans, while obesity impacts nearly 42% of the U.S. adult population. Research into these conditions is often complex and spans decades. For instance, the landmark Diabetes Control and Complications Trial (DCCT) and its follow-up study, EDIC, have been funded for over 40 years. Such foundational research would be impossible under a regulatory framework that allows for the sudden, politically motivated withdrawal of support.
Official Responses and Broadening Opposition
The Endocrine Society is not alone in its opposition. While it has taken a leading role, the proposed OMB rule has drawn criticism from a broad coalition of scientific organizations, including the American Association for the Advancement of Science (AAAS), the Association of American Medical Colleges (AAMC), and the Federation of American Societies for Experimental Biology (FASEB).
In a joint statement, several of these organizations argued that the rule would "undermine the transparency and accountability that are the hallmarks of the American research enterprise." They noted that the peer-review system is designed to ensure that the best science is funded, regardless of which party holds the White House. By inserting political appointees into the approval chain, the OMB risks creating a "chilling effect" where researchers avoid pursuing innovative but controversial ideas for fear of losing their livelihoods.
On Capitol Hill, the reaction has been notably bipartisan. While Senator Susan Collins has led the effort in the Senate, many House Democrats and Republicans have expressed similar concerns about executive overreach. Lawmakers have noted that the power to direct federal spending rests with Congress, and the OMB’s attempt to redefine grant criteria through administrative rulemaking may infringe upon legislative authority.
Analysis of Implications: The Global Context
The implementation of the OMB rule could have long-lasting negative implications for the United States’ global standing in science and technology. For decades, the U.S. has been the destination of choice for the world’s most talented scientists, largely because of the stability and integrity of its funding systems. If the U.S. moves toward a model where research is directed by political mandates rather than scientific inquiry, it risks a "brain drain" as top-tier talent seeks opportunities in Europe or Asia, where merit-based systems remain the standard.
Furthermore, the proposed restrictions on international collaboration are particularly ill-timed. Modern science is an inherently global endeavor. Whether it is tracking the evolution of a virus or identifying genetic markers for rare diseases, researchers must be able to collaborate across borders without the fear that their funding will be pulled due to shifting geopolitical priorities. The OMB rule’s focus on restricting international ties could isolate American scientists and slow the pace of global medical breakthroughs.
The rule also poses a threat to the "Open Science" movement. In recent years, federal policy has trended toward making research results freely available to the public. By limiting the ability of researchers to use grant funds for publication costs, the OMB rule could force scientists to publish in "paywalled" journals, thereby limiting the impact of their work and creating barriers for smaller institutions and the general public to access critical scientific data.
The Path Forward and Final Considerations
As the October 1 deadline nears, the focus remains on the halls of Congress. The inclusion of delay language in the Senate’s funding resolution is a pivotal first step, but it is not a permanent solution. The Endocrine Society and its partner organizations are continuing to advocate for a full withdrawal of the proposed rule or, failing that, a legislative "fix" that explicitly protects the peer-review process from executive interference.
The Society’s leadership has emphasized that their fight is not against any specific administration or political party, but rather in defense of the scientific method itself. By ensuring that research remains driven by curiosity, evidence, and peer validation, the scientific community aims to protect the health and well-being of the American public.
The outcome of this regulatory battle will likely set a precedent for how federal science is funded for the next generation. If the OMB rule is allowed to stand, it could signal the end of an era of independent scientific inquiry in the United States, replacing it with a system where the pursuit of truth is secondary to the pursuit of political alignment. For the Endocrine Society and the thousands of researchers they represent, this is a risk the nation cannot afford to take. The coming weeks will be decisive in determining whether the U.S. continues to uphold the principles of merit-based science or pivots toward a more controlled and politicized research environment.
